 Therapy renal cell carcinoma lymphokine-activated killer cells phase II experience hybrid bolus continuous infusion regimen Forty-seven patients metastatic unresectable renal cell carcinoma lymphokine-activated killer LAK -cell therapy hybrid regimen intravenous bolus U/kg Cetus Corp Emeryville CA hours days priming phase continuous infusion days second treatment period vitro-generated LAK cells selection patients good performance status PS PS PS nephrectomy patients low tumor burden response rate low complete CRs partial responses PRs overall objective response rate Toxicity comparable high-dose bolus regimen results dose schedule administration likelihood response renal cell carcinoma